These challenges may foster abbreviated evaluations, with some clinicians prematurely diagnosing “unexplained chronic cough” and “refractory chronic cough” in patients who have not been ...

The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores ...

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...

Trevi Therapeutics’ stock value has shot up more than 53% after its investigational therapy Haduvio (nalbuphine hydrochloride ...

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal ...

Haduvio reduced 24-hour cough frequency by 67% from baseline and 57% vs. placebo in Trevi's Phase 2a trial for refractory chronic cough. 84% of Haduvio patients saw at least a 30% cough reduction vs.

Refractory chronic cough, affecting approximately 2-3 million individuals in the U.S., is persistent and remains untreated as no therapies are approved, causing serious complications and economic ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients ...

Shorthand for ‘Refractory Chronic Cough Improvement Via Nalbuphine ER’, the River trial saw patients dosed with Haduvio for 21 days followed by a 21-day washout period. Patients received ...